 monday 18 may 2020 09 51 am early data frommodernainc s covid 19 vaccine the first to be tested in the united states showed that it produced protective antibodies in a small group of healthy volunteers the company said on monday the data comes from eight people who took part in a 45 subject safety trial that kicked off in march themodernavaccine is one of more than 100 under development intended to protect against the novel coronavirus that has infected more than 4 7 million people globally and killed over 315 000 overall the study showed the vaccine was safe and all study participants produced antibodies against the virus an analysis of the response in the eight individuals showed that those who received a 100 microgram dose and a 25 microgram dose had levels of protective antibodies to fend of the virus that exceeded those found in the blood of people who recovered from covid 19 the illness caused by the coronavirus the news issued in a release by the u s biotechnology company lifted moderna shares mrna 20 and helped drive the broader stock market higher these are significant findings but it is a phase 1 clinical trial that only included eight people it was designed for safety not for efficacy said dr amesh adalja in infectious disease expert at the johns hopkins center for health security who was not involved in the study the very early data offers a glimmer of hope for a vaccine among the most advanced in development adalja said many glitches can occur between now and the time this vaccine is tested for efficacy in thousands of people what we do see is encouraging he said scientists are trying to understand what level of antibodies will ultimately prove protective against the novel coronavirus and how long that protection will last modernasaid the vaccine appeared to show a dose response meaning that people who the 100 mcg dose produced more antibodies than people who got the lower dose the vaccine has gotten the green light to start the second stage of human testing last week u s regulators gave the vaccine fast track status to speed up the regulatory review in the phase ii or midstage trial designed to further test effectiveness and find the optimal dose modernasaid it will drop plans to test a 250 mcg dose and test a 50 mcg dose instead reducing the dose required to produce immunity could help spare the amount of vaccine required in each shot meaning the company could ultimately produce more of the vaccine maximizing number of doses in the context of a pandemic we expect demand to far outstrip supply and the lower the dose the more people we expect to be able to protect said chief medical officer tal zaks the u s government in april placed a big bet onmoderna backing its vaccine with 483 million from the biomedical advanced research and development authority barda a part of the u s department of health and human services hhs the company said that grant will enable it to supply millions of doses per month in 2020 and with further investments tens of million a month in 2021 if the vaccine proves successful in may modernastuck a 10 year strategic collaboration with lonza group that over time will allow the manufacture of up to 1 billion doses a year we are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from sars cov 2 modernachief executive officer st phane bancel said using the official name for the new virus modernasaid it expects to start a larger late stage or phase iii trial in july there are currently no approved treatments or vaccines for covid 19 and experts predict a safe and effective vaccine could take 12 to 18 months to develop the most notable side effects reported from the early testing ofmoderna s vaccine were three participants with flu like symptoms following a second shot of the highest dose the company said it believed the symptoms were an indirect measure of a strong immune response 2020 thomson reuters all rights reserved newsmax comment policy keep discussions on topic avoid personal attacks and threats of any kind links will not be permitted newsmax moneynews newsmax health and independent american are registered trademarks of newsmax media inc newsmax tv and newsmax world are trademarks of newsmax media inc 